MPI researchers develop homogeneous hydrogenolysis reaction with molecular palladium catalyst

The new tritiation reaction is practical and robust to execute and could have an immediate impact in the discovery and development of pharmaceuticals.
Photo: Frank Vinken / MPI für Kohlenforschung

New method enables simple tritium labeling and could provide added value to the discovery and development of pharmaceuticals. The new tritiation reaction is practical and robust to execute and could have an immediate impact in the discovery and development of pharmaceuticals.

Tritium 3H, a radioactive isotope of hydrogen, is commonly used in medicinal chemistry as a label to follow the course of a drug in the human body. Chemists like to use the technique to evaluate drug candidates and their metabolism. However, synthesis of the radiolabeled molecules is challenging.

A team led by Professor Tobias Ritter of the Department of Organic Synthesis at the Max-Planck-Institut für Kohlenforschung has now found a new way to label complex small molecules with tritium. In a joint research project with the development department of the Swiss pharmaceutical company Roche, they investigated ways to incorporate tritium into pharmaceuticals and other similar molecules that may be important derivatives for the drug industry.

The team took advantage of the special properties of arylthianthrenium salts that they developed two years ago. The thianthrene group can be introduced into pharmaceuticals selectively and at a late stage in a direct and predictable manner. “The unusual feature of this work is the reaction of arylpseudohalides with hydrogen, catalyzed for the first time by a homogeneous catalyst,” explains Tobias Ritter. “Such reaction were previously unknown with conventional groups that can be introduced into pharmaceuticals. Normally, chemists use heterogeneous catalysts but those also often destroy other functional groups, which are frequently found in pharmaceuticals,” the director annotates.
The new approach does not require an inert atmosphere or dry conditions, making it practical to use.

The researchers present their research results in the leading scientific journal Nature.

Wissenschaftliche Ansprechpartner:

Prof. Dr. Tobias Ritter, Director of the Department of Organic Synthesis at the Max-Planck-Institut für Kohlenforschung, 0208-306-2414

Originalpublikation:

Title: Tritiation of aryl thianthrenium salts with a molecular palladium catalyst
Link: https://www.nature.com/articles/s41586-021-04007-y
Authors: Da Zhao, Roland Petzold, Jiyao Yan, Dieter Muri & Tobias Ritter

https://www.kofo.mpg.de

Media Contact

Isabel Schiffhorst Presse- und Öffentlichkeitsarbeit
Max-Planck-Institut für Kohlenforschung

All latest news from the category: Life Sciences and Chemistry

Articles and reports from the Life Sciences and chemistry area deal with applied and basic research into modern biology, chemistry and human medicine.

Valuable information can be found on a range of life sciences fields including bacteriology, biochemistry, bionics, bioinformatics, biophysics, biotechnology, genetics, geobotany, human biology, marine biology, microbiology, molecular biology, cellular biology, zoology, bioinorganic chemistry, microchemistry and environmental chemistry.

Back to home

Comments (0)

Write a comment

Newest articles

Distance learning can improve women’s access to vocational training as animal health care practitioners in Nepal. Image Credit: Heifer International

Hybrid Job Training Boosts Women’s Participation in Nepal

Globally, women’s workforce participation is about 25% lower than men’s, often due to barriers such as domestic responsibilities and cultural norms. Vocational training can increase employment opportunities, but women may…

CO2release increase under repeated drying-rewetting cycles (DWCs). Image Credit: Suzuki, Nagano et al., 2025 SOIL

Drying and Rewetting Cycles Boost Soil CO2 Emissions

Niigata, Japan – The amount of carbon dioxide (CO2) released by microbial decomposition of soil organic carbon on a global scale is approximately five times greater than the amount of…

A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new mothers. Oregon State's Olena Taratula and collaborators including OSU postdoctoral researcher Babak Mamnoon and Maureen Baldwin, a physician at Oregon Health & Science University, designed a type of drug nanocarrier known as a polymersome to specifically target a protein in choriocarcinoma cells. Depicted is a polymersome with its methotrexate cargo. Illustration by Parinaz Ghanbari. Image Credit: Parinaz Ghanbari

Improved Treatment Method for Rare Pregnancy-Related Cancer

PORTLAND, Ore. – A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new mothers, and it has potential with other…